Publications by authors named "Yupei Guo"

PARP inhibitors sensitize pancreatic ductal adenocarcinoma (PDAC) to radiation by inducing DNA damage and replication stress. These mechanisms also have the potential to enhance radiation-induced type I interferon (T1IFN)-mediated antitumoral immune responses. We hypothesized that the PARP inhibitor olaparib would also potentiate radiation-induced T1IFN to promote antitumor immune responses and sensitization of otherwise resistant PDAC to immunotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Radiotherapy is the main treatment for a deadly type of brain cancer in kids called diffuse midline glioma (DMG), which has a special genetic mutation (H3K27M).
  • Researchers found that this mutation makes the tumors weaker against radiation when combined with a medicine called PARP inhibitor (like olaparib), which can help fight the cancer.
  • The study showed that using PARP inhibitors with radiotherapy also boosts the immune system, allowing it to attack the cancer cells better, which could be an important new treatment for kids with DMG.
View Article and Find Full Text PDF

Diffuse intrinsic pontine glioma (DIPG) is a highly malignant brain tumor that mainly occurs in children with extremely low overall survival. Traditional therapeutic strategies, such as surgical resection and chemotherapy, are not feasible mostly due to the special location and highly diffused features. Radiotherapy turns out to be the standard treatment method but with limited benefits of overall survival.

View Article and Find Full Text PDF

PLA2G6-associated neurodegeneration (PLAN, NBIA2) is the second most common type of neurodegeneration with brain iron accumulation (NBIA), caused by recessive mutations of PLA2G6 gene, which encodes Ca-independent phospholipase Aβ (iPLAβ). In most PLAN cases, decreased iPLAβ activity and iron deposition was observed meanwhile, and researchers also identified a PLA2G6 mutation family without iron deposition shown by MRI images. This brought us the question of whether decreased iPLAβ activity was the cause of iron deposition in PLAN.

View Article and Find Full Text PDF

Phospholipase A2 group VI (PLA2G6)-associated neurodegeneration (PLAN) includes a series of neurodegenerative diseases that result from the mutations in . PLAN has genetic and clinical heterogeneity, with different mutation sites, mutation types and ethnicities and its clinical phenotype is different. The clinical phenotypes and genotypes of PLAN are closely intertwined and vary widely.

View Article and Find Full Text PDF

Small interfering RNA (siRNA)-induced RNA degradation can specifically inhibit viral infection and has been extensively investigated for its efficacy as an antiviral therapeutic approach. In this study we constructed a lentivirus vector carrying a U6-short hairpin RNA expression cassette to express siRNAs in vero cells. The lentivirus vector also expressed an enhanced green fluorescence protein as a reporter.

View Article and Find Full Text PDF

Triosephosphate isomerase (TPI), a glycolytic enzyme, functions in catalyzing the interconversion of glyceraldehyde-3-phosphate and dihydroxyacetone phosphate and is generally upregulated in tumours. However, there are data suggesting loss in lymphomas. To determine its effects in chicken embryonal fibroblasts (CEF) a plasmid was constructed to allow transfection.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Yupei Guo"

  • - Yupei Guo's recent research primarily focuses on the therapeutic strategies for pediatric high-grade brain tumors, specifically H3K27M diffuse midline glioma, exploring the efficacy of PARP inhibitors in enhancing radiotherapy and boosting antitumor immune responses.
  • - Additionally, Guo is investigating the use of engineered extracellular vesicles as innovative diagnostic and therapeutic tools for aggressive pediatric tumors like diffuse intrinsic pontine glioma (DIPG), addressing the challenges associated with traditional treatment modalities.
  • - His earlier studies have delved into PLA2G6-associated neurodegeneration, providing insights on the genetic and clinical diversity of the condition, and exploring the mechanistic aspects of neurodegeneration without iron accumulation in patients, contributing to a better understanding of this rare disease.